<DOC>
	<DOCNO>NCT01386099</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics pharmacodynamics PSN821 patient type 2 diabetes . Subjects assess beta-cell function use hyperglycaemic clamp start treatment end 12 week treatment period primary endpoint . HbA1c , fast plasma glucose body weight secondary endpoint .</brief_summary>
	<brief_title>A PK-PD Study PSN821 Type 2 Diabetes Patients ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients Type 2 diabetes accord American Diabetes Association criterion , diagnose least 12 month prior screen . Male female , 18 75 year age , inclusive . Body Mass Index 25 45 kg/m2 , inclusive . Diabetes manage stable regimen diet , exercise metformin monotherapy ( without dosage adjustment within 4 week prior screen ) . Haemoglobin A1c ( HbA1c ) 7.5 10 % screening . Fasting plasma glucose ( FPG ) 7 13.3 mmol/L screen Day 1 . Males , whose partner able comply contraceptive advice . Females non childbearing potential . Willing sign write Informed Consent Form ( ICF ) participate study abide study restriction . Patients Type 1 diabetes maturity onset diabetes young secondary form diabetes , due pancreatitis . Marked diabetic complication . Illness medication impact scientific integrity study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>